Medicxi's mega-startup Centessa rolls out first data for hemophilia drug with plans to charge ahead into pivotal test
When Medicxi earlier this year cobbled together Centessa — its Russian nesting doll of a biotech startup with 10 portfolio companies folded into one — the focus from the start was on the promise of each startup’s lead drug. The first of those candidates is now rolling out data, and it’s sure to add some weight to Centessa’s ambitious mission.
Centessa subsidiary ApcinteX turned over a topline win for hemophilia A/B candidate SerpinPC with the drug nailing early bleed rate checkpoints with what the biotech called a manageable safety profile, according to early Phase IIa data released Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,600+ biopharma pros reading Endpoints daily — and it's free.